Dr. Morris on Bone Biomarkers for Radium-223 in Prostate Cancer

Michael J. Morris, MD
Published: Saturday, Feb 18, 2017



Michael J. Morris, MD, Memorial Sloan Kettering Cancer Center, discusses bone biomarkers for radium-223 dichloride (Xofigo) in castration-resistant prostate cancer.

In a phase I/IIa clinical trial, the effects of radium-223 with docetaxel (Taxotere) versus docetaxel alone on bone biomarkers was found that the patients who received the combination regimen had a greater decline in tALP and bone formation markers bALP and P1NP.

According to Morris, these bone biomarkers are important because they are one of the most closely associated tests to survival.
 


Michael J. Morris, MD, Memorial Sloan Kettering Cancer Center, discusses bone biomarkers for radium-223 dichloride (Xofigo) in castration-resistant prostate cancer.

In a phase I/IIa clinical trial, the effects of radium-223 with docetaxel (Taxotere) versus docetaxel alone on bone biomarkers was found that the patients who received the combination regimen had a greater decline in tALP and bone formation markers bALP and P1NP.

According to Morris, these bone biomarkers are important because they are one of the most closely associated tests to survival.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication
x